Shattuck Labs (NASDAQ:STTK) Stock Price Down 6.9% – Here’s What Happened

Posted by Francis Steltz on Oct 15th, 2026

Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) shares traded down 6.9% on Tuesday. The company traded as low as $5.70 and last traded at $5.67. Approximately 1,120,788 shares changed hands during trading, an increase of 15% from the average session volume of 971,356 shares. The stock had previously closed at $6.09.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on STTK shares. Leerink Partners assumed coverage on Shattuck Labs in a research report on Monday, July 20th. They set an “outperform” rating and a $16.00 price objective for the company. UBS Group began coverage on Shattuck Labs in a research report on Sunday. They issued a “buy” rating and a $17.00 target price on the stock. TD Cowen raised Shattuck Labs to a “strong-buy” rating in a research report on Monday, August 24th. Raymond James Financial initiated coverage on shares of Shattuck Labs in a research note on Monday, August 24th. They issued a “strong-buy” rating and a $18.00 price objective on the stock. Finally, Needham & Company LLC boosted their price objective on shares of Shattuck Labs from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Shattuck Labs currently has an average rating of “Buy” and an average price target of $13.70.

View Our Latest Report on STTK

Shattuck Labs Price Performance

The stock has a market cap of $541.46 million, a P/E ratio of -10.58 and a beta of 1.09. The firm’s 50-day moving average price is $6.69 and its 200-day moving average price is $6.52.

Shattuck Labs (NASDAQ:STTK – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). Sell-side analysts expect that Shattuck Labs, Inc. will post -0.45 earnings per share for the current year.

Institutional Trading of Shattuck Labs

Institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP acquired a new stake in Shattuck Labs in the second quarter worth about $12,269,000. Frazier Life Sciences Management L.P. acquired a new position in Shattuck Labs during the second quarter valued at $26,025,000. Bank of New York Mellon Corp purchased a new stake in shares of Shattuck Labs in the second quarter worth about $1,516,000. The Manufacturers Life Insurance Company acquired a new stake in Shattuck Labs during the second quarter worth about $1,576,000. Finally, BlackRock Inc. acquired a new stake in Shattuck Labs during the second quarter worth about $27,315,000. 58.74% of the stock is currently owned by institutional investors.

About Shattuck Labs

(Get Free Report)

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create biologic medicines that combine immune checkpoint blockade with immune-cell activation in a single therapeutic construct.

Shattuck’s pipeline has included investigational ARC fusion proteins intended to alter the tumor microenvironment and stimulate immune responses against cancer cells.